BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yen RD, Bonatti H, Mendez J, Aranda-michel J, Satyanarayana R, Dickson RC. Case Report of Lamivudine-Resistant Hepatitis B Virus Infection Post Liver Transplantation from a Hepatitis B Core Antibody Donor: De Novo HB Infection from an HB Core Antibody Donor . American Journal of Transplantation 2006;6:1077-83. [DOI: 10.1111/j.1600-6143.2006.01313.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
Number Citing Articles
1 Tillmann HL. Lamivudine-resistant hepatitis B virus infection post-liver transplantation from a hepatitis B core antibody donor. Am J Transplant 2006;6:1980; author reply 1981. [PMID: 16780541 DOI: 10.1111/j.1600-6143.2006.01421.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
2 Jankowska I, Pawłowska J, Teisseyre M, Kaliciński P, Kamiński A, Czubkowski P, Cielecka-kuszyk J, Kluge P, Pronicki M, Socha J. Prevention of de Novo Hepatitis B Virus Infection by Vaccination and High Hepatitis B Surface Antibodies Level in Children Receiving Hepatitis B Virus Core Antibody-Positive Living Related Donor Liver: Case Reports. Transplantation Proceedings 2007;39:1511-2. [DOI: 10.1016/j.transproceed.2006.11.013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
3 Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B Immune Globulin in Liver Transplantation Prophylaxis: An Update. Hepat Mon 2012;12:168-76. [DOI: 10.5812/hepatmon.5124] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
4 Huprikar S, Danziger-Isakov L, Ahn J, Naugler S, Blumberg E, Avery RK, Koval C, Lease ED, Pillai A, Doucette KE, Levitsky J, Morris MI, Lu K, McDermott JK, Mone T, Orlowski JP, Dadhania DM, Abbott K, Horslen S, Laskin BL, Mougdil A, Venkat VL, Korenblat K, Kumar V, Grossi P, Bloom RD, Brown K, Kotton CN, Kumar D. Solid organ transplantation from hepatitis B virus-positive donors: consensus guidelines for recipient management. Am J Transplant. 2015;15:1162-1172. [PMID: 25707744 DOI: 10.1111/ajt.13187] [Cited by in Crossref: 133] [Cited by in F6Publishing: 101] [Article Influence: 19.0] [Reference Citation Analysis]
5 Bonatti H, Sawyer R, Dickson RC, Razonable R, Schmitt T, Mendez J, Singh N, Pruett T. Transmission of viral disease to the recipient through the donor liver: . Current Opinion in Organ Transplantation 2007;12:231-41. [DOI: 10.1097/mot.0b013e32814e6b67] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
6 Fernández I, Pascasio JM, Colmenero J; en nombre del grupo de trabajo para el VII consenso de la SETH., Autores participantes en el grupo de trabajo en representación de sus respectivos programas de trasplante hepático. Prophylaxis and treatment in liver transplantation. VII Consensus Document of the Spanish Society of Liver Transplantation. Gastroenterol Hepatol 2020;43:169-77. [PMID: 32094045 DOI: 10.1016/j.gastrohep.2019.11.005] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Roche B, Roque-Afonso AM, Sebagh M, Delvart V, Duclos-Vallee JC, Castaing D, Samuel D. Escape hepatitis B virus mutations in recipients of antibody to hepatitis B core antigen-positive liver grafts receiving hepatitis B immunoglobulins. Liver Transpl. 2010;16:885-894. [PMID: 20583085 DOI: 10.1002/lt.22084] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 1.8] [Reference Citation Analysis]
8 Takemura N, Sugawara Y, Tamura S, Makuuchi M. Liver transplantation using hepatitis B core antibody-positive grafts: review and university of Tokyo experience. Dig Dis Sci. 2007;52:2472-2477. [PMID: 17805972 DOI: 10.1007/s10620-006-9656-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
9 Umeda M, Marusawa H, Ueda M, Takada Y, Egawa H, Uemoto S, Chiba T. Beneficial effects of short-term lamivudine treatment for de novo hepatitis B virus reactivation after liver transplantation. Am J Transplant 2006;6:2680-5. [PMID: 17049057 DOI: 10.1111/j.1600-6143.2006.01542.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
10 Perrillo R. Hepatitis B virus prevention strategies for antibody to hepatitis B core antigen-positive liver donation: a survey of North American, European, and Asian-Pacific transplant programs. Liver Transpl. 2009;15:223-232. [PMID: 19177436 DOI: 10.1002/lt.21675] [Cited by in Crossref: 58] [Cited by in F6Publishing: 50] [Article Influence: 4.5] [Reference Citation Analysis]
11 Singer AL, Kucirka LM, Namuyinga R, Hanrahan C, Subramanian AK, Segev DL. The high-risk donor: viral infections in solid organ transplantation: . Current Opinion in Organ Transplantation 2008;13:400-4. [DOI: 10.1097/mot.0b013e3283094ba3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 8] [Article Influence: 1.8] [Reference Citation Analysis]
12 Yataco ML, Dickson RC, Bonatti H, Aranda-michel J, Mendez J, Ghabril M, Nguyen J. Dual hepatitis virus infections in liver transplant: case report and a review of the literature. Clinical Transplantation 2009;23:282-8. [DOI: 10.1111/j.1399-0012.2008.00929.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
13 Bohorquez HE, Cohen AJ, Girgrah N, Bruce DS, Carmody IC, Joshi S, Reichman TW, Therapondos G, Mason AL, Loss GE. Liver transplantation in hepatitis B core-negative recipients using livers from hepatitis B core-positive donors: a 13-year experience. Liver Transpl. 2013;19:611-618. [PMID: 23526668 DOI: 10.1002/lt.23644] [Cited by in Crossref: 30] [Cited by in F6Publishing: 20] [Article Influence: 3.8] [Reference Citation Analysis]
14 Lee S, Kim JM, Choi GS, Park JB, Kwon CH, Choe YH, Joh JW, Lee SK. De novo hepatitis b prophylaxis with hepatitis B virus vaccine and hepatitis B immunoglobulin in pediatric recipients of core antibody-positive livers. Liver Transpl. 2016;22:247-251. [PMID: 26600319 DOI: 10.1002/lt.24372] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
15 Lee YJ, Oh SH, Kim KM, Song SM, Namgoong JM, Kim DY, Lee SG. De novo hepatitis B virus infection after pediatric liver transplantations with hepatitis B core antibody-positive donors: a single-center 20-yr experience. Pediatr Transplant. 2015;19:267-272. [PMID: 25648049 DOI: 10.1111/petr.12432] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
16 Chang MS, Olsen SK, Pichardo EM, Heese S, Stiles JB, Abdelmessih R, Verna EC, Guarrera JV, Emond JC, Brown RS. Prevention of de novo hepatitis B with adefovir dipivoxil in recipients of liver grafts from hepatitis B core antibody-positive donors. Liver Transpl. 2012;18:834-838. [PMID: 22422699 DOI: 10.1002/lt.23429] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
17 Dindoost P, Jazayeri SM, Alavian SM. Hepatitis B immune globulin in liver transplantation prophylaxis: an update. Hepat Mon. 2012;12:168-176. [PMID: 22550524 DOI: 10.5812/hepatmon.832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
18 Scuderi V, Ceriello A, Santaniello W, Aragiusto G, Romano M, Migliaccio C, Calise F. Hepatitis B prophylaxis in hepatitis B-negative recipients transplanted with donor grafts positive for hepatitis B core antibodies. Transplant Proc. 2011;43:271-273. [PMID: 21335203 DOI: 10.1016/j.transproceed.2010.09.100] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
19 Nam H, Nilles KM, Levitsky J, Ison MG. Donor-derived Viral Infections in Liver Transplantation. Transplantation 2018;102:1824-36. [PMID: 29979345 DOI: 10.1097/TP.0000000000002326] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Article Influence: 3.3] [Reference Citation Analysis]
20 Zhou K, Zhou S. Risk of disease transmission in an expanded donor population: the potential of hepatitis B virus donors. Curr Opin Organ Transplant 2020;25:631-9. [PMID: 33027191 DOI: 10.1097/MOT.0000000000000810] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
21 Brandl A, Stolzlechner P, Eschertzhuber S, Aigner F, Weiss S, Vogel W, Krannich A, Neururer S, Pratschke J, Graziadei I. Inferior graft survival of hepatitis B core positive grafts is not influenced by post-transplant hepatitis B infection in liver recipients-5-year single-center experience. Transpl Int. 2016;29:471-482. [PMID: 26716608 DOI: 10.1111/tri.12741] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
22 Vizzini G, Gruttadauria S, Volpes R, D’Antoni A, Pietrosi G, Filì D, Petridis I, Pagano D, Tuzzolino F, Santonocito MM. Lamivudine monoprophylaxis for de novo HBV infection in HBsAg-negative recipients with HBcAb-positive liver grafts. Clin Transplant. 2011;25:E77-E81. [PMID: 21039887 DOI: 10.1111/j.1399-0012.2010.01329.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
23 Yu L, Koepsell T, Manhart L, Ioannou G. Survival after orthotopic liver transplantation: the impact of antibody against hepatitis B core antigen in the donor. Liver Transpl. 2009;15:1343-1350. [PMID: 19790164 DOI: 10.1002/lt.21788] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.4] [Reference Citation Analysis]
24 Pan JJ, Thosani N, Machicao VI, Fallon MB. Current use of hepatitis B immune globulin for prevention of de novo hepatitis B in recipients receiving anti-HBc-positive livers. Hepatol Int 2011;5:635-43. [PMID: 21484133 DOI: 10.1007/s12072-010-9250-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
25 Sasadeusz J, Grigg A, Hughes PD, Lee Lim S, Lucas M, McColl G, McLachlan SA, Peters MG, Shackel N, Slavin M, Sundararajan V, Thompson A, Doyle J, Rickard J, De Cruz P, Gish RG, Visvanathan K. Screening and Prophylaxis to Prevent Hepatitis B Reactivation: Transplant Recipients. Clin Liver Dis 2019;23:493-509. [PMID: 31266623 DOI: 10.1016/j.cld.2019.04.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
26 Park JB, Kwon CH, Lee KW, Choi GS, Kim DJ, Seo JM, Kim SJ, Joh JW, Lee SK. Hepatitis B virus vaccine switch program for prevention of de novo hepatitis B virus infection in pediatric patients. Transpl Int. 2008;21:346-352. [PMID: 18208419 DOI: 10.1111/j.1432-2277.2007.00618.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
27 Avelino-Silva VI, D’Albuquerque LA, Bonazzi PR, Song AT, Miraglia JL, De Brito Neves A, Abdala E. Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature. Clin Transplant. 2010;24:735-746. [PMID: 20438579 DOI: 10.1111/j.1399-0012.2010.01254.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 3.1] [Reference Citation Analysis]
28 Prieto M. Antibody to hepatitis B core antigen-positive grafts: Not perfect but no longer marginal: Editorial. Liver Transpl 2009;15:1164-8. [DOI: 10.1002/lt.21814] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
29 Chotiyaputta W, Pelletier SJ, Fontana RJ, Lok AS. Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010;4:707-15. [PMID: 21286341 DOI: 10.1007/s12072-010-9188-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
30 Buzo BF, Ramos JF, Marques Rossetti RA, Salles N, Mendrone-Júnior A, Rocha V, de Seixas Santos Nastri AC. Hepatitis B virus among hematopoietic stem cell transplant recipients: Antiviral impact in seroconversion, engraftment, and mortality in a Latin American center. Transpl Infect Dis 2020;22:e13243. [PMID: 31901206 DOI: 10.1111/tid.13243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]